Previous 10 | Next 10 |
THE WOODLANDS, Texas, April 27, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended March 31, 2020. “We achieved 17% growth in XERMELO net sales for the first quarter o...
THE WOODLANDS, Texas, April 22, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2020 financial results on Monday, April 27, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m...
THE WOODLANDS, Texas, April 07, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will host its 2020 annual meeting of stockholders in a virtual format only due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of mee...
While I’m sure die-hards will claim that Lexicon Pharmaceutical ’s ( LXRX ) sotagliflozin still has a future, the company’s recent announcement that it would shut down the SCORED and SOLOIST long-term studies and indefinitely postpone an NDA filing due to an inability to ...
Mylan Resurrects Old Malaria Medication to Fight COVID-19 Mylan ( MYL ) reported that it has decided to restart the production of hydroxychloroquine sulfate tablets. The restart is to allow the use of these tablets as potential treatment of COVID-19. It is expected that the tablets will be...
Citing dim prospects of a near-term partnership to provide funding and uncertainties related to the COVID-19 outbreak, Lexicon Pharmaceuticals (NASDAQ: LXRX ) will shut down two long-term outcomes trials, SCORED and SOLOIST , designed support the use of Zynquista (sotagliflozin) for chr...
THE WOODLANDS, Texas, March 19, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today provided an update on its Zynquista TM (sotagliflozin) program in type 2 diabetes, heart failure and chronic kidney disease. The company will close out early the two l...
Lexicon Pharmaceuticals (NASDAQ: LXRX ) perks up 11% premarket on light volume on the heels of data from a retrospective pre- and post-design chart review of 200 metastatic neuroendocrine tumor patients on standard background therapies who received Xermelo (telotristat ethyl) f...
THE WOODLANDS, Texas, March 13, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s ® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the European Neur...
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2019 Results Conference Call March 12, 2020 08:00 AM ET Company Participants Dr. Kimberly Lee - Head, IR and Corporate Strategy Lonnel Coats - President and CEO Alex Santini - EVP and Chief Commercial Officer Dr. Pablo Lapuerta - EVP and ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...